Overview
The Chen laboratory studies how cancer and its immune microenvironment sense and respond to stresses and therapeutic insults to evade immune surveillance and develop drug resistance. We specialize in ER stress, Unfolded Protein Response (UPR), immunology, cancer biology, biochemistry, transgenic and preclinical animal models. Our research aims to elucidate the significance and mechanisms of stress responses in therapy resistance and anti-tumor immunity, and develop mechanism-based novel therapies to overcome therapy resistance and transform cancer to a manageable chronic disease (Nat Rev Cancer, 2021). Our study published in JCI revealed a critical role of the IRE1a/XBP1 branch of the UPR in mediating chemotherapy resistance and led to the first-in-human clinical trial of IRE1a RNase inhibitor. Our efforts in understanding proteostasis regulation revealed the direct cross-talk between oncogenic signaling and the protein quality control machinery and uncovered the mechanisms that account for the proteostasis rewiring in response to KRAS inhibition, allowing the drug-resistant cells to escape oncogenic KRAS addiction and gain resistance (Science, 2023). Another research area of the Chen laboratory focuses on ER Associated Degradation (ERAD). We recently discovered the crosstalk between ERAD complex and UPR in maintaining proteostasis and niche interactions (Nat Cell Biol, 2020, eLife, 2021).
Dr. Chen is board certified in Board Certification - Internal MedicineAmerican Board Of Internal MedicineBoard Certification - Hematology And Medical OncologyAmerican Board Of Internal Medicine. She is actively involved in clinical research, co-authoring 5 peer reviewed articles. Dr. Chen is currently accepting new patients.
Specialties
Licenses
Board Certifications
Hospital Affiliations
Languages Spoken
Gender
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE SNP
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- OTHER MANAGED MEDICAID
- MANAGED MEDICAID PLAN
- MEDICARE-MEDICAID PLAN
- OTHER COMMERCIAL
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
2525 A Holly Hall St, Houston, TX 77054
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Baylor College Of Medicine
Dr. Mothaffar F. Rimawi is a board-certified medical oncologist specializing in breast cancer care and research. He is Professor at the Department of Medicine, Section of Hematology and Oncology at Baylor College of Medicine. Dr. Rimawi is also Executive Medical Director & Associate Director of Clinical Affairs and Co-Leader of the Breast Cancer Program at BCM’s Dan L Duncan Comprehensive Cancer Center. Additionally, he serves as Chief of the Oncology Service Line at St Luke's Health in Houston.Dr. Rimawi’s professional interests include: the diagnosis, treatment and management of breast cancer; clinical trials in breast cancer; neoadjuvant therapy; targeted therapy and biomarkers in breast cancer; treatment resistance to ER and HER2-targeted therapies in breast cancer; locally advanced breast cancer; and breast disease and cancer.Dr. Rimawi received his medical degree from the University of Jordan in Amman, Jordan. He completed his residency in Internal Medicine and fellowships in Medical Oncology and Hematology and Breast Cancer at BCM. Dr. Rimawi holds certifications in Internal Medicine and Medical Oncology from the American Board of Internal Medicine. He is a member of the American College of Physicians, American Society of Clinical Oncology and the American Medical Association.In addition to English, Dr. Rimawi speaks Arabic. Dr. Rimawi is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Breast Cancer, HER-2 Positive Breast Cancer, Triple-Negative Breast Cancer, and Paget Disease of the Breast. Dr. Rimawi is currently accepting new patients.
Office
Hagop Kantarjian is an Oncologist practicing medicine in Houston, Texas. Dr. Kantarjian is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Bone Marrow Aspiration, and Splenectomy.
Baylor College Of Medicine
Dr. Julie Nangia is a medical oncologist who specializes in the care of patients with breast cancer. Dr. Nangia is Medical Director of Breast Oncology at the Breast Care Center at the Dan L Duncan Comprehensive Cancer Center and an Associate Professor of Medicine at the Lester and Sue Smith Breast Center at Baylor College of Medicine. She is also the Director of the Breast Cancer Prevention and High Risk Clinic at BCM, where she is a Faculty Senator.Dr. Nangia’s clinical interests include: hereditary breast cancer, breast cancer prevention, and metastatic triple negative breast cancer.Dr. Nangia received her medical degree from the University of Missouri-Kansas City. She completed her residency in internal medicine at The University of Texas Health Science Center in Houston and a hematology-oncology fellowship at Rush University Medical Center in Chicago, Illinois.Dr. Nangia is board certified in internal medicine and medical oncology. Dr. Nangia is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Familial Pancreatic Cancer, and HER-2 Positive Breast Cancer. Dr. Nangia is currently accepting new patients.
Frequently Asked Questions about Dr. Natalie C. Chen
How do I make an appointment with Dr. Natalie C. Chen?
You can book an appointment with Dr. Natalie C. Chen by calling their office at 713-526-4243. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.
Does Dr. Natalie C. Chen accept my insurance?
Dr. Natalie C. Chen accepts most major insurance plans, including Aetna and Cigna. We recommend calling the office directly at 713-526-4243 to verify that your specific plan is currently accepted before your visit.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
We do not have enough information to identify the Areas of Expertise for this provider.